None listed
Conditions
Interventions
Drug : Among patients who underwent new-generation drug-eluting stent implantation, comparision between a group with ezetimibe 10mg/high-intensity atorvastatin 40mg combination therapy orally administ
Sponsors
Yonsei University Health System, Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 19-85 years 2. Patients who underwent coronary revascularization with newer generation DES implantation
Exclusion criteria
Exclusion criteria: 1. Allergy or hypersensitive to ezetimibe or statin 2. Active liver disease or persistent unexplained serum AST/ALT elevation more than 2 times the upper limit of normal range 3. History of any adverse drug reaction requiring discontinuation of statin 4. Pregnant women, women with potential childbearing, or lactating women 5. Life expectancy less than 3 years 6. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator 7. Inability to understand or read the informed content
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of all-cause death, myocardial infarction (MI), any coronary revascularization, hospitalization for unstable angina, or nonfatal stroke | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of subjects achieving target LDL-cholesterol 4 x UNL);Elevation of hepatic enzymes (AST, ALT, or both > 3 x UNL);Elevation of serum creatinine level (>50% from baseline) ;Change of proteinuria ;Diagnosis of cancer ;Operation due to cataract | — |
Countries
Korea, Republic of
Contacts
Public ContactYong-Jun Lee
Yonsei University Health System, Severance Hospital
Outcome results
None listed